Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials


Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04123314

Organisation Name: Johns Hopkins University

Overal Status: Recruiting

Start Date: December 18, 2020

Last Update: November 24, 2020

Lead Sponsor: Johns Hopkins University

Brief Summary: This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.

Conditions:
  • Depressive Symptoms
  • Depression
  • Alzheimer Disease
  • Mild Cognitive Impairment


Total execution time in seconds: 0.15078592300415